Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study

JAAD Int. 2021 Jul 31:4:67-69. doi: 10.1016/j.jdin.2021.06.001. eCollection 2021 Sep.

Jorge R Georgakopoulos¹, Tina Felfeli^{2

3}, Aaron M Drucker^{1

3

4}, Christine E Jo⁵, Vincent Piguet^{1

4}, Jensen Yeung^{1

4

6

7}

¹ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
² Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
³ Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
⁴ Women's College Hospital, Toronto, Ontario, Canada.
⁵ Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
⁶ Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
⁷ Probity Medical Research Inc, Waterloo, Ontario, Canada.

No abstract available

Keywords: adverse event; atopic dermatitis; drug survival; dupilumab; efficacy; safety.